Nordson (NDSN) Q4 2025 Earnings Transcript

Nordson reported record fiscal 2025 EBITDA of $900 million, adjusted EPS of $10.24 (+5%), and annual free cash flow of $661 million, while maintaining gross margins near 55% despite tariffs. Fourth-quarter sales rose 1% to $752 million and adjusted EPS increased 9% to $3.03, with EBITDA margin expanding 160 bps to 34%; the company also returned $479 million to shareholders via buybacks and dividends. Management guided fiscal 2026 sales to +1% to +6% and adjusted EPS to +6% to +12%, citing a 5% higher backlog, stabilization in industrial and automotive end markets, and continued benefits from portfolio restructuring.

Analysis

The key signal is not the headline margin beat; it’s that the company is converting a mixed-demand environment into higher-quality earnings through portfolio pruning and working-capital discipline. That creates a rerating path because the market usually discounts industrials on cyclical revenue volatility, but here the incremental dollar of revenue is starting to look more durable and more cash generative. The leverage reduction gives them optionality to either accelerate buybacks or do small-to-mid bolt-ons without stressing the balance sheet, which should keep downside in the equity limited unless end-market data rolls over sharply.

The second-order takeaway is that the medical reset appears to have changed the earnings mix in a way the market may underappreciate. If the upper-30s margin level is the new steady state rather than a one-quarter spike, then the business has effectively de-risked its margin structure, making EPS more resilient even if industrial volumes stay patchy. That matters because the guidance range still embeds caution around industrial and ATS timing; if those segments simply stabilize rather than reaccelerate, the company can beat consensus through mix and leverage alone.

The bigger debate is whether investors are overfocusing on the low end of guidance and underweighting the setup for 2H acceleration. Backlog improvement, troughing in polymer processing and automotive, and a still-strong semiconductor-related demand base suggest the first quarter may be the softest comparison, not the peak of the cycle. The risk is that ATS remains lumpy and x-ray/industrial recovery lags, but that mainly delays upside rather than breaks the thesis unless macro weakens or capex/order timing slips again.

Key Decisions for Investors

• Long NDSN into the next 2-4 weeks on any post-call consolidation; risk/reward favors a 5-8% upside move if the market starts to price in sustained upper-30s medical margins and normal seasonality.
• Buy NDSN Jan-2027 calls or call spreads to express the thesis that earnings quality improves faster than top-line growth; the catalyst is multiple expansion from cash conversion and leverage reduction over the next 2-3 quarters.
• Pair trade: long NDSN / short a more cyclical industrial peer with weaker cash conversion and higher leverage over the next 3-6 months; NDSN has better downside defense if macro remains choppy.
• If using shares, add on dips below the 50-day average rather than chasing strength; the main risk is ATS timing noise, which can create entry points without impairing the longer-duration thesis.